Dr Sharman
Module 1: Role of Covalent Bruton Tyrosine Kinase (BTK) Inhibitors for Newly Diagnosed CLL
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Dr Broadway-Duren
Module 1
Cool A et al. BTK inhibitors: Past, present, and future. Trends Pharmacol Sci 2024;45(8):691-707. Abstract
Module 4: CAR (Chimeric Antigen Receptor) T-Cell Therapy for R/R CLL
Jain MD et al. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 2023;141(20):2430-42. Abstract
Dr Fakhri
Module 2: Role of Time-Limited Up-Front Treatment, Including Therapy Combining BTK Inhibitors and Venetoclax, for Newly Diagnosed CLL
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. EHA 2023;Abstract S145.
Brown JR et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial. ASH 2024;Abstract 1009.
Burger JA et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020;34(3):787-98. Abstract
Shanafelt TD et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381(5):432-43. Abstract
Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: Scientific rationale and clinical results. Blood Cancer J 2021;11(4):79. Abstract
Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract
Module 3: Role of Pirtobrutinib for Relapsed/Refractory (R/R) CLL
Robak T et al. The role of bruton's kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers (Basel). 2022 Feb 2;14(3):771. Abstract
Sharman JP et al. BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2024;Abstract 886.
Woyach JA et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study. ASH 2023;Abstract 325.